ST Premium
For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.
Ready to Win Big?
Try Now for Just $1!APTO Company Profile and Key Details
Aptose Biosciences Inc.
APTO Stock Price Chart
Stock Price Today
Aptose Biosciences Inc. (APTO) stock declined over -18.26%, trading at $0.16 on NASDAQ, down from the previous close of $0.19. The stock opened at $0.24, fluctuating between $0.15 and $0.18 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, which is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS; and APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. It has agreements with CrystalGenomics, Inc. and OHM Oncology. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
Company Information
| Employees | 35 |
| Beta | 0.91 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Aptose Biosciences Inc. (NASDAQ: APTO) stock price is $0.16 in the last trading session. During the trading session, APTO stock reached the peak price of $0.18 while $0.15 was the lowest point it dropped to. The percentage change in APTO stock occurred in the recent session was -18.26% while the dollar amount for the price change in APTO stock was -$0.03.
The NASDAQ listed APTO is part of Biotechnology industry that operates in the broader Healthcare sector. Aptose Biosciences Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Ms. Janet Clennett C.A.
Vice President of Fin.
Mr. Roger Davies B.Sc.
Vice President of Operations
Mr. Philippe Ledru
Senior Vice President & Chief Commercial Officer
Dr. Rafael Bejar M.D., Ph.D.
Senior Vice President & Chief Medical Officer
Dr. William G. Rice Ph.D.
Chairman, Pres, Chief Executive Officer & Chief Accounting Officer
Dr. Marc Wiles Ph.D.
Senior Vice President of Regulatory Affairs
Mr. Brooks Ensign M.B.A.
Vice President & Controller
Mr. Fletcher Payne
Senior Vice President, Chief Financial Officer & Sec.
APTO's closing price is 46.15% higher than its 52-week low of $0.13 where as its distance from 52-week high of $1.94 is -90.21%.
Number of APTO employees currently stands at 35.
Official Website of APTO is: https://www.aptose.com
APTO could be contacted at phone 165 071 85028 and can also be accessed through its website. APTO operates from 251 Consumers Road, Toronto, ON M2J 4R3, Canada.
APTO stock volume for the day was 6.81M shares. The average number of APTO shares traded daily for last 3 months was 12.72M.
The market value of APTO currently stands at $9.35M with its latest stock price at $0.16 and 60.18M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com